London
8 °C
Manchester
Glasgow
Dublin
Belfast
Washington
Denver
23 °C
Atlanta
26 °C
Dallas
30 °C
Houston Texas
New Orleans
27 °C
El Paso
Phoenix
Los Angeles
6 °C
7 °C
24 °C
22 °C
1 °C
3 °C
13 °C
Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / Redwood AI Corp. (CSE:AIRX)(Frankfurt:Y0N, WKN:A422EZ) ("Redwood" or the "Company") is pleased to announce that its Chief Executive Officer, Louis Dron, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program highlighting leaders shaping important industries and ideas. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In the interview, Dron discussed how Vancouver-based Redwood AI is building an artificial intelligence platform designed to help address one of the pharmaceutical industry's biggest bottlenecks by improving how compounds are evaluated, tested, and scaled from early discovery through commercialization, while also highlighting the broader applicability of Redwood's chemistry AI platform in areas such as defense, where rapid chemical analysis, risk assessment, and secure deployment may be important.
During the interview, Dron explained how Redwood's platform uses AI, cheminformatics, and large-scale reaction data to help chemists evaluate manufacturing paths in seconds, compare trade-offs across cost, safety, scalability, and environmental impact, and make faster, better-informed decisions across the drug development life cycle. He also discussed the growing challenge facing pharmaceutical companies as they review tens of thousands, and in some cases millions, of compounds while trying to identify which ones are worth advancing.
The conversation touched on the broader relevance of Redwood's technology beyond pharmaceutical development. Dron noted that chemistry sits at the heart of many industries, including environmental applications, materials science, Agri-tech, and defense-related fields. Redwood has begun seeing interest in its AI chemistry platform from organizations exploring potential uses in areas such as chemical hazard and threat screening, rapid characterization of unknown compounds, analysis of chemical signatures, and assessment of precursor chemical supply chains. The Company believes this growing cross-sector interest reflects the flexibility of the same core technology it is developing for pharmaceutical discovery, development and manufacturing.
Dron also discussed Redwood's focus on efficient, secure deployment. He noted that the Company's chemistry-focused models can be installed locally, including in air-gapped environments, which may be important where security, sovereignty, and intellectual property protection are key considerations.
"Being featured on Conversations That Matter gave us a valuable opportunity to explain the problem and how we are solving it," said Louis Dron, Chief Executive Officer of Redwood AI. "We are focused on helping improve chemical decision-making across pharmaceutical development, and we are encouraged by the broader interest we are seeing in how this technology could support other chemistry-driven applications, including potential applications in defense and public safety."
You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Facebook page, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times.
About Redwood AI Corp.
Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI's platform enables faster, more efficient development of new therapies and chemistry-driven applications.
ON BEHALF OF REDWOOD AI CORP.,
"Louis Dron"
Chief Executive Officer
For more information, please contact:
Louis Dron
Chief Executive Officer
Tel: +1 888 530 8488
[email protected]
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains statements and information that, to the extent they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information is generally identified by words such as "believe", "expect", "anticipate", "estimate", "intend", "plan", "may", "should", "will", "potential" and similar expressions and, in this news release, includes statements relating to the development and potential deployment of the Company's AI-powered platform and to the safety enhancements made thereto, and the expectation that the platform may be utilized for dug discovery or development or to further defense or safety solutions. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on it, as actual results may differ materially from those expressed or implied. Forward-looking information inherently involves risks and uncertainties, many of which are beyond the Company's control. The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise, except as required by applicable laws.
SOURCE: Redwood AI Corp.
View the original press release on ACCESS Newswire
S.Cloutier--SMC
